Suneel Gupta Selected Research

levodopa drug combination carbidopa (Nakom)

9/2019	Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations.
1/2019	Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules.
3/2018	Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
1/2018	Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease.
1/2018	Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations.
2/2017	Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
1/2017	Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.
4/2015	Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
1/2015	Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
12/2014	Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Suneel Gupta Research Topics

Disease

13	Parkinson Disease (Parkinson's Disease) 09/2019 - 04/2013
7	Fibrosis (Cirrhosis) 10/2022 - 10/2014
5	Dyskinesias (Dyskinesia) 03/2018 - 05/2013
4	Cicatrix (Scar) 10/2022 - 01/2016
4	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 06/2011 - 11/2002
3	Wounds and Injuries (Trauma) 10/2022 - 10/2019
2	Pain (Aches) 01/2022 - 12/2005
2	Toxic Optic Neuropathy 12/2021 - 01/2018
2	Ulcerative Colitis 12/2021 - 11/2021
2	Sleep Initiation and Maintenance Disorders (Insomnia) 12/2014 - 04/2013
2	Nausea 02/2014 - 04/2013
2	Acute Pain 01/2005 - 01/2005
2	Hypertension (High Blood Pressure) 07/2004 - 01/2002
1	Erythema 12/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 12/2021
1	Lacrimal Apparatus Diseases (Epiphora) 12/2021
1	Blepharospasm 12/2021
1	Inflammation (Inflammations) 11/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 04/2021
1	Corneal Neovascularization 01/2021
1	Disease Progression 01/2021
1	Corneal Opacity 10/2019
1	Burns 01/2019
1	Intraoperative Complications 01/2017
1	Corneal Injuries 01/2017
1	Blister (Bulla) 01/2016
1	Endophthalmitis (Ophthalmia) 01/2016
1	Glaucoma 01/2016
1	Corneal Edema 01/2016
1	Cataract (Cataracts) 01/2016
1	Confusion (Bewilderment) 12/2014
1	Chronic Kidney Failure (Chronic Renal Failure) 10/2014
1	Peritonitis 10/2014
1	Peritoneal Fibrosis 10/2014
1	Dizziness (Lightheadedness) 02/2014
1	Headache (Headaches) 02/2014
1	Premature Ejaculation 03/2006
1	Urge Urinary Incontinence (Urge Incontinence) 02/2002
1	Body Weight (Weight, Body) 01/2002

Drug/Important Bio-Agent (IBA)

13	levodopa drug combination carbidopa (Nakom)FDA LinkGeneric 09/2019 - 04/2013
8	Levodopa (L Dopa)FDA LinkGeneric 01/2018 - 04/2013
4	AlkaliesIBA 10/2022 - 01/2018
4	Methylphenidate (Ritalin)FDA LinkGeneric 06/2011 - 11/2002
3	Fentanyl (Sublimaze)FDA LinkGeneric 12/2005 - 01/2005
2	SolutionsIBA 10/2022 - 01/2018
2	SaltsIBA 10/2022 - 01/2018
2	IntegrinsIBA 12/2021 - 11/2021
2	Peptides (Polypeptides)IBA 12/2021 - 11/2021
2	DecorinIBA 01/2021 - 10/2014
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2021 - 01/2016
2	Hematoxylin (Haematoxylon)IBA 01/2021 - 01/2016
2	CollagenIBA 11/2020 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 01/2018
2	Capsules (Microcapsules)IBA 01/2017 - 05/2013
2	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2017 - 10/2014
2	Verapamil (Calan)FDA LinkGeneric 07/2004 - 01/2002
1	Trypan Blue FDA Link 01/2022
1	Local AnestheticsIBA 01/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2022
1	BromidesIBA 01/2022
1	Ophthalmic Solutions (Eye Drops)IBA 01/2022
1	Glutathione (Reduced Glutathione)IBA 04/2021
1	Acrolein (Aqualin)IBA 04/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2021
1	Sodium Hydroxide (Caustic Soda)FDA Link 10/2019
1	Biological ProductsIBA 10/2019
1	Monoamine Oxidase (MAO)IBA 03/2018
1	Dopamine Agonists (Dopamine Agonist)IBA 03/2018
1	entacapone (Comtan)FDA Link 03/2018
1	Amantadine (Aman)FDA LinkGeneric 03/2018
1	PolyethyleneimineIBA 01/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	TRAM 34IBA 01/2018
1	Ion Channels (Ion Channel)IBA 01/2018
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2018
1	GoldIBA 01/2018
1	Carbidopa (Lodosyn)FDA LinkGeneric 02/2017
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2017
1	Actins (F Actin)IBA 01/2016
1	Histone Deacetylase InhibitorsIBA 01/2016
1	Vorinostat FDA Link 01/2016
1	Proteoglycans (Proteoglycan)IBA 10/2014
1	ZymosanIBA 10/2014
1	Delayed-Action PreparationsIBA 04/2013
1	Therapeutic UsesIBA 06/2011
1	dapoxetineIBA 03/2006
1	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 03/2006
1	Pain-FreeIBA 12/2005
1	Morphine (MS Contin)FDA LinkGeneric 12/2005
1	Analgesics (Analgesic Drugs)IBA 01/2005
1	oxybutynin (Tavor)FDA LinkGeneric 02/2002
1	Pharmaceutical PreparationsIBA 02/2002

Therapy/Procedure

6	Therapeutics 12/2021 - 10/2014
5	Slit Lamp 12/2021 - 01/2016
1	Aftercare (After-Treatment) 12/2021
1	Euthanasia (Mercy Killing) 10/2019
1	Photorefractive Keratectomy 01/2017
1	Filtering Surgery 01/2016
1	Peritoneal Dialysis 10/2014